Last reviewed · How we verify
BL - 1020
BL-1020 is a vasopressin V2 receptor antagonist.
BL-1020 is a vasopressin V2 receptor antagonist. Used for Diabetic nephropathy.
At a glance
| Generic name | BL - 1020 |
|---|---|
| Sponsor | BioLineRx, Ltd. |
| Drug class | Vasopressin V2 receptor antagonist |
| Target | V2 receptor |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 2 |
Mechanism of action
It works by blocking the action of vasopressin at the V2 receptor, leading to increased urine production and reduced water reabsorption in the kidneys.
Approved indications
- Diabetic nephropathy
Common side effects
- Diarrhea
- Nausea
- Headache
Key clinical trials
- Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia (PHASE2, PHASE3)
- Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 (PHASE2)
- A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study (PHASE2)
- A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer (PHASE1)
- Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BL - 1020 CI brief — competitive landscape report
- BL - 1020 updates RSS · CI watch RSS
- BioLineRx, Ltd. portfolio CI